HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

2- phenyl- 5- (pyrrolidin- 1- yl)- 1- (3,4,5- trimethoxybenzyl)- 1H- benzimidazole

an antineoplastic agent that disrupts microtubules; structure in first source

Also Known As:

PPTMB cpd

Networked: 1 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Experts

1.	Chang, Chih-Shiang: 1 article (08/2010)
2.	Chang, Kai-Wei: 1 article (08/2010)
3.	Chang, Wei-Ling: 1 article (08/2010)
4.	Chiang, Po-Cheng: 1 article (08/2010)
5.	Guh, Jih-Hwa: 1 article (08/2010)
6.	Ho, Yunn-Fang: 1 article (08/2010)
7.	Liu, Ju-Fang: 1 article (08/2010)

Related Diseases

1.

Prostatic Neoplasms (Prostate Cancer)

08/01/2010 - "Several pharmacological and biochemical assays were used to characterize signalling pathways of 2-phenyl-5-(pyrrolidin-1-yl)-1-(3,4,5-trimethoxybenzyl)-1H-benzimidazole (PPTMB), a benzimidazole analogue, in prostate cancer cells. "
08/01/2010 - "2-Phenyl-5-(pyrrolidin-1-yl)-1-(3,4,5-trimethoxybenzyl)-1H-benzimidazole, a benzimidazole derivative, inhibits growth of human prostate cancer cells by affecting tubulin and c-Jun N-terminal kinase."

Related Drugs and Biologics

1.	JNK Mitogen-Activated Protein Kinases
2.	Tubulin
3.	benzimidazole